AXSM logo

AXSMAxsome Therapeutics Inc

$245.64
$10.50
(4.46%)
Today
Closed $245.64
$0.64
(0.26%)
After Hours
Updated: 07:55 PM EDT
EarningsAug 3
Mkt Cap$12.1B
Vol918,050.00
News
all
press releases
Why Is Mirum Pharmaceuticals (MIRM) Down 10.1% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
More News
News Placeholder
Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?
Ocugen (OCGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Why Is Axsome (AXSM) Down 0.4% Since Last Earnings Report?
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks
News Placeholder
Insider Selling: Axsome Therapeutics (NASDAQ:AXSM) COO Sells 233 Shares of Stock
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark Jacobson sold 233 shares of the stock in a transaction on Tuesday, May 5th. The stock was sold at an average price of $228.18, for a total value of $53,165.94. Following the transaction, the chief operating officer owned 4,517...
MarketBeat
News Placeholder
Mark Jacobson Sells 4,517 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) COO Mark Jacobson sold 4,517 shares of the firm's stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $227.94, for a total transaction of $1,029,604.98. Following the sale, the chief operating officer...
MarketBeat
News Placeholder
AXSM Q1 Loss Widens, Revenues Jump on Higher Auvelity Sales
Axsome posts a wider Q1 loss but revenues jump 57%, driven by strong Auvelity and Sunosi sales.
Zacks
News Placeholder
Axsome Therapeutics (NASDAQ:AXSM) Stock Price Expected to Rise, Morgan Stanley Analyst Says
Morgan Stanley upped their price target on Axsome Therapeutics from $217.00 to $242.00 and gave the company an 'equal weight' rating in a report on Tuesday...
MarketBeat
News Placeholder
Wells Fargo & Company Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $255.00
Wells Fargo & Company upped their price objective on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the company an 'overweight' rating in a research note on Tuesday...
MarketBeat
News Placeholder
Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $310.00 at Mizuho
Mizuho increased their target price on Axsome Therapeutics from $228.00 to $310.00 and gave the company an 'outperform' rating in a report on Tuesday...
MarketBeat
News Placeholder
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Given Average Rating of "Moderate Buy" by Brokerages
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) has earned an average recommendation of "Moderate Buy" from the twenty-one brokerages that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eighteen h...
MarketBeat
<
1
2
...
>

Advertisement|Remove ads.